FDAapproval95% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (bladder cancer) as Pfizer; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Bladder Cancer
- Sub-indication
- Bladder Cancer
Related signal: FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment